NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Objective
Primary Objective Phase II: To compare investigator-assessed progression free survival (PFS) between atezolizumab plus radiotherapy and atezolizumab alone
Phase III: To compare overall survival (OS) between atezolizumab plus radiotherapy and atezolizumab alone
Secondary Objectives To assess the toxicity between the atezolizumab plus radiotherapy arm and the atezolizumab arm To assess the impact of adding radiotherapy on PFS and OS in patients with 1-3 visible tumors and >3 visible tumors To assess the impact of adding radiotherapy on PFS and OS in patients receiving consolidation radiotherapy to all visible disease ( complete consolidation ) and patients who do not receive consolidation radiation to all visible disease ( incomplete consolidation )
Exploratory Objectives To assess the association between pre-treatment tumor burden (determined by central radiographic assessment, using both tumor number and tumor volume), and PFS and OS benefit
